Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA

Journal of the National Cancer Institute

Volumn 89, Issue 5, 1997, Pages 365-373

  Dixit, Mniralini ^a   Yang, Jin Long ^a   Poirier, Miriam C ^b   Price, James O ^c   Andrews, Paul A ^d   Arteaga, Carlos L ^c,e,f  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e VANDERBILT INGRAM CANCER CENTER   (United States)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; COMPLEMENTARY RNA; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADOLESCENT; APOPTOSIS; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DNA DAMAGE; DNA DRUG COMPLEX; DRUG SENSITIVITY; ETIOLOGY; FEMALE; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUDE MOUSE; RECEPTOR BINDING; RECEPTOR DENSITY;

EID: 0031041268     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.5.365     Document Type: Article

References (55)

1. Carpenter G, Wahl MI. The epidermal growth factor family of mitogens. In: Sporn MB, Roberts AB, editors. Handbook of experimental pharmacology, Vol 95/I: Peptide growth factors and their receptors I. Heidelberg: Springer-Verlag, 1989:69-171.
2. Downward J, Yarden Y, Mayes E, Srace G, Totty N, Stockwell P, et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984;307:521-7.
3. Di Fiore PP, Pierce JH, Fleming TP, Hazan R, Ullrich A, King CR, et al. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 1987;51:1063-70.
4. Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 1991;47:87-98.
5. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1983;1:511-29.
6. Fan Z, Masui H, Altas I, Mendelsohn J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of the 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1993;53:4322-8.
7. Ennis BW, Valverius EM, Bates SE, Lippman ME, Bellot F, Kris R, et al. Anti-epidermal growth factor receptor antibodies inhibit the autocrine-stimulated growth of MDA-468 human breast cancer cells. Mol Endocrinol 1989;3:1830-8.
8. Fan Z, Lu Y, Wu X, Mendelsohn J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 1994;269: 27595-602.
9. Christen RD, Hom DK, Porter DC, Andrews PA, MacLeod CL, Hafstrom L, et al. Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J Clin Invest 1990;86:1632-40.
10. Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J, Sela M. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mouse. J Natl Cancer Inst 1988;80: 1605-11.
11. Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993;53:4637-42.
12. Bravo R, Burckhardt J, Curran T, Muller R. Simulation and inhibition of growth by EGF in different A431 cell clones is accompanied by the rapid induction of c-fos and c-myc proto-oncogenes. EMBO J 1985;4: 1193-8.
13. Taetle R, Castagnola J, MacLeod C. Induction of c-fos by an anti-epidermal growth factor receptor monoclonal antibody. Biochem Biophys Res Commun 1989;158:129-35.
14. Fan Z, Mendelsohn J, Masui H, Kumar R. Regulation of epidermal growth factor receptor in NIH3T3/HER14 cells by antireceptor monoclonal antibodies. J Biol Chem 1993;268:21073-9.
15. lyn tyrosine kinase activation in mammalian cells treated with mitomycin C. Oncogene 1994;9:3005-11.
16. Pawson T, Schlessinger J. Signal transduction by receptor tyrosine kinases. Curr Biol 1993;3:434-42.
17. c-src with two major signaling pathways in human breast cancer. Proc Natl Acad Sci U S A 1994;91:83-7.
18. Moroni MC, Willingham MC, Beguinot L. EGF-R antisense RNA blocks expression of the epidermal growth factor receptor and suppresses the transforming phenotype of a human carcinoma cell line. J Biol Chem 1992;267:2714-22.
19. Arteaga CL, Hurd SD, Dugger TC, Winnier AR, Robertson JB. Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor α-Pseudomonas exotoxin 40 fusion protein. Cancer Res 1994;54:4703-9.
20. Limbird LE. Identification of receptors using direct radioligand binding techniques. In: Limbird LE, editor. Cell surface receptors: a short course on theory and methods. Boston: Martinus Nijhoff Publishing, 1986: 51-96.
21. Munson PJ, Rodbard D. LIGAND: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 1980;107: 220-39.
22. Sambrook J, Fritsch EF, Maniatis T, editors. Molecular cloning: a laboratory manual. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press, 1989:16.59-16.62.
23. Armstrong DK, Isaacs JT, Ottaviano YL, Davidson NE. Programmed cell death in an estrogen-independent human breast cancer cell line, MDA-MB-468. Cancer Res 1992;52:3418-24.
24. Gorczyca W, Bruno S, Darzynkiewicz RJ, Gong J, Darzynkiewicz Z. DNA strand breaks occurring during apoptosis: their early in situ detection by the terminal deoxynucleotidyl transferase and nick translation assays and prevention by serine protease inhibitors. Int J Oncol 1992;1:639-48.
25. 1 and S phases of the cell cycle without growth arrest or stabilization of wild-type p53. Mol Cell Biol 1994;14:4183-92.
26. Zinkewich-Peotti K, Andrews PA. Loss of cis-diamminedichloro-platinum(II) resistance in human ovarian carcinoma cells selected for rhodamine 123 resistance. Cancer Res 1992;52:1902-7.
27. erbB-2 signaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res 1994;54: 3758-65.
28. Shamkhani H, Anderson LM, Henderson CE, Moskal TJ, Runowicz CD, Dove LF, et al. DNA adducts in human and patas monkey maternal and fetal tissues induced by platinum drug chemotherapy. Reprod Toxicol 1994;8:207-16.
29. Reed E, Gupta-Burt S, Litterst CL, Poirier MC. Characterization of the DNA damage recognized by an antiserum elicited against cis-diamminedichloroplatinum (II)-modified DNA. Carcinogenesis 1990;11: 2117-21.
30. Filmus J, Trent JM, Pollak MN, Buick RN. Epidermal growth factor receptor gene-amplified MDA-468 breast cancer cell line and its nonamplified variants. Mol Cell Biol 1987;7:251-7.
31. Nishina Y, Nakagoshi H, Imamoto F, Gonda TJ, Ishii S. Trans-activation by the c-myb proto-oncogene. Nucleic Acids Res 1989;17:107-17.
32. Sorenson CM, Eastman A. Mechanism of cis-diamminedichloroplatinum-(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res 1988;48:4484-8.
33. 2 phase and cell death induced by cisplatin. J Natl Cancer Inst 1990;82:749-55.
34. Barry MA, Behnke CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 1990;40:2353-62.
35. Wyllie AH, Kerr JF, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1980;68:251-306.
36. Fichtinger-Schepman AM, van der Veer JL, den Hartog JH, Lohman PH, Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum (II) with DNA: formation, identification, and quantification. Biochemistry 1985;24:707-13.
37. Zamble DB, Lippard SJ. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 1995;20:435-9.
38. Eastman A, Schulte N. Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum (II). Biochemistry 1988;27:4730-4.
39. Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 1994;269:787-90.
40. Drewinko B, Patchen M, Yang LY, Barlogie B. Differential killing efficacy of twenty antitumor drugs on proliferating and nonproliferating human tumor cells. Cancer Res 1981;41:2328-33.
41. Reed E, Dabholkar M, Chabner B. Platinum analogs. In: Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy. 2nd ed. Philadelphia: Lippincott-Raven Publishers, 1996:357-78.
42. Reed E, Yuspa SH, Zwelling LA, Ozols RF, Poirier MC. Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J Clin Invest 1986;77:545-50.
43. Nishikawa K, Rosenblum MG, Newman RA, Pandita TK, Hittelman WN, Donato NJ. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor. Cancer Res 1992;52:4758-65.
44. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994;1198:165-84.
45. Pietras RJ, Fendly BM, Chazin VR, Pergram MD, Howell SB, Slamon DJ. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994;9:1828-38.
46. erbB-2 protein and alterations in growth properties and responses to therapy in an ovarian tumor cell line. Cell Growth Differ 1994;5: 1367-72.
47. Weernink PA, Rijksen G. Activation and translocation of c-Src to the cytoskeleton by both platelet-derived growth factor and epidermal growth factor. J Biol Chem 1995;270:2264-7.
48. Osherov N, Levitzki A. Epidermal-growth-factor-dependent activation of the src-family kinases. Eur J Biochem 1994;225:1047-53.
49. Basu A, Cline JS. Oncogenic transformation alters cisplatin-induced apoptosis in rat embryo fibroblasts. Int J Cancer 1995;63:597-603.
50. Soderquist AM, Todderud GT, Carpenter G. Elevated membrane association of phospholipase C-γ 1 in MDA-468 mammary tumor cells. Cancer Res 1992;52:4526-9.
51. Hanauske AR, Osborne CK, Chamness GC, Clark GM, Forseth BJ, Buchok JB, et al. Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents. Eur J Cancer Clin Oncol 1987;23:545-51.
52. Fanidi A, Harrington EA, Evan GI. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 1992;359:554-6.
53. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
54. Chen MJ, Holskin B, Strickler J, Gorniak J, Clark MA, Johnson PJ, et al. Induction by E1A oncogene expression of cellular susceptibility to lysis by TNF. Nature 1987;330:581-3.
55. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994; 78:539-42.